Weiwei Xu

Safety and Immunogenicity of SW-BIC-213, a Modified COVID-19 Lipo-Polyplex mRNA Vaccine, in Laotian Healthy Adults Aged 18 Years and Above: A Phase 1/2 Trial

Background/Objectives: Messenger RNA vaccines can induce strong immune responses, but delivery, biodistribution, and storage stability remain important considerations. We evaluated the safety and immunogenicity of SW-BIC-213, a Lipo-Polyplex (LPP)-based mRNA vaccine against SARS-...